Global Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Parenteral and Oral), By Drug Type (Analgesics, DMARDs, Corticosteroids), By Regional Outlook and Forecast, 2

Global Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Parenteral and Oral), By Drug Type (Analgesics, DMARDs, Corticosteroids), By Regional Outlook and Forecast, 2023 - 2029


The Global Musculoskeletal Disorders Drugs Market size is expected to reach $109.4 billion by 2029, rising at a market growth of 4.2% CAGR during the forecast period.

Asia Pacific is one of the major contributors of the market as China, Japan, and India have aged population, thus capturing approximately 2/5th share of the market by 2029. For instance, over 60% of Japan's population is aged 30 and above. By 2050, most of the global population aged 60 and above is projected to be in low- and middle-income nations. The rise in life expectancy has led to a growing aging population. This emerging trend is advantageous for the market as it leads to a rise in the incidence of musculoskeletal diseases due to the illness's high prevalence in old adults and boosts the demand for its treatments, resulting in market expansion.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2022, The Johnson & Johnson Medical Devices Companies collaborated with Microsoft for expanding its digital surgery ecosystem. In addition, Pfizer came into collaboration with Sirana Pharma focusing on investigating treatment for a rare bone disease, through leveraging Sirana’s microRNA targeting approach.

Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson, Novartis AG, and Pfizer, Inc. are the forerunners in the Market. In March, 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer’s Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness. Companies such as AbbVie, Inc., Amgen, Inc., and UCB S.A. are some of the key innovators in Market.

COVID-19 Impact Analysis

The COVID-19 pandemic caused supply chain disruptions in several end-user industries, including food and beverage, healthcare, and industrial. In addition, the COVID-19-led economic slowdown resulted in a drop in the market for musculoskeletal disorders drugs. Since the COVID-19 pandemic disrupted supply chains and slowed down clinical studies and drug development, it had a considerable effect on the market for medications for musculoskeletal problems. Due to a drop in sales of medications for musculoskeletal disorders, including analgesics, the market for musculoskeletal disorders drugs shrank during the period. However, a rebound in the market is forecasted, and the musculoskeletal disease medications market is expected to continue growing steadily in the years to come.

Market Growth Factors

Musculoskeletal diseases are extremely common

There are more than 150 diseases and conditions that are categorized as musculoskeletal impairments. These impairments are characterized by muscle, bone, joint, and adjacent connective tissue dysfunction. These dysfunctions can result in temporary or permanent restrictions on functioning and involvement. According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries. Musculoskeletal problems afflict people of all ages; however, the prevalence differs by age and diagnosis. As more people suffer from musculoskeletal problems, there will likely be a greater need for pharmaceuticals to treat them, accelerating market expansion.

Higher alcohol consumption

At both the individual and societal levels, numerous variables that influence alcohol consumption levels, patterns, and the scope of alcohol-related issues in populations have been found. Poorer cultures experience more negative health effects and social implications from drinking at a given level and pattern of drinking than wealthier ones. Men account for 7.7% of all fatalities globally from alcohol-related causes, compared to women, who account for 2.6% of all deaths. In addition, male drinkers used 19.4 liters of pure alcohol on average per person in 2016, whereas female drinkers consumed 7.0 liters on average. As there is a link between higher rates of joint diseases and greater alcohol use, the market is anticipated to develop as a result of rising alcohol consumption throughout the projected period.

Market Restraining Factors

Insufficient availability of healthcare professionals

Projected for 2035, a shortage of 12.9 million healthcare professionals is anticipated, representing an increase from the current 7.2 million deficit. As per the recent research published by WHO, it has been observed that the dearth of healthcare professionals can significantly impact the health of billions of individuals globally if prompt action is not taken. Factors contributing to this phenomenon include an aging workforce, resulting in retirements or departures for higher-paying positions without corresponding replacements. Also, there is a shortage of new entrants and inadequate training in the industry. Insufficient healthcare personnel in different regions of the world will negatively impact the identification and management of ailments such as musculoskeletal disorders, reducing the need for associated medications and hindering market expansion.

Drug Type Outlook

Based on drug type, the market is segmented into analgesics, DMARDs, corticosteroids and others. The analgesics segment dominated the market with maximum revenue share in 2022. This is due to the affordability of analgesics, which is increasing their demand in the market as medications for musculoskeletal disorders. Additionally, they come in a variety of strengths, from moderate to powerful, and many of these are available over the counter at the local drugstore or grocery store. Thus, their affordability and availability as OTC is expected to boost the segment's expansion.

Route of Administration Outlook

On the basis of route of administration, the market is divided into oral and parenteral. The oral segment procured a substantial revenue share in the market in 2022. This is owing to the fact many patients choose oral drugs over other kinds of treatment because they are easier to administer and less expensive. Due to its many benefits, the oral administration route is favored above the many alternative medication delivery methods. These benefits include dependability to accommodate different drug types, safety, excellent patient compliance, simplicity of intake, pain avoidance, and versatility. The benefits associated with the oral route will drive the market segment's expansion.

Distribution Channel Outlook

By distribution channel, the market is classified into hospital pharmacies, online providers and drug stores & retail pharmacies. The drug stores & retail pharmacies segment witnessed the largest revenue share in the market in 2022. This is due to a growth in the number of patients suffering from musculoskeletal ailments such as rheumatoid arthritis, which raises the demand for pharmaceuticals in drug stores and retail pharmacies. Also, these stores are able to provide a much more personalized solution to the customer's complication, and the patient can have their medication instantly. The easy availability of drugs, combined with other factors, is expected to increase the segment's growth.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. The market is expanding due to the presence of numerous key companies and improvements in the region's medicine production for musculoskeletal disorders. Additionally, the market is anticipated to develop due to a solid healthcare infrastructure, significant purchasing power, and an increased adoption rate of analgesics and other medications for musculoskeletal disorders. Additionally, there has been an increase in the prevalence of musculoskeletal illnesses due to several causes, such as obesity, sedentary lifestyles, and workplace injuries, which has led to a rise in the demand for medications to treat these conditions, propelling the market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.

Recent Strategies Deployed in Musculoskeletal Disorders Drugs Market

Acquisitions and Mergers:

Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer’s Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.

Mar-2022: UCB took over Zogenix, a US-based developer of therapeutic solutions. The addition of Zogenix expands and reinforces the acquiring company's market presence and reinforces its sustainable patient value strategy.

Oct-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobio's antibody platform to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.

Partnerships, Collaborations and Agreements:

Jun-2022: Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana’s microRNA targeting approach.

Jan-2022: The Johnson & Johnson Medical Devices Companies collaborated with Microsoft, a US-based technology company. The collaboration involves expanding the medical devices company's digital surgery ecosystem.

Feb-2021: UCB extended its collaboration agreement with Microsoft, a US-based technology company. The agreement involves advancing drug discovery and development. The collaboration integrates Microsoft's cloud, AI, computational services, and UCS's drug discovery abilities, and aims at identifying more effective molecules.

Geographical Expansions:

Sep-2022: AbbVie expanded its already existing facility located in Cork. The expansion includes building a new manufacturing facility and bringing in new technologies.

Approvals and Trials:

Apr-2022: AbbVie received FDA clearance for its RINVOQ. RINVOQ is intended for the treatment of ankylosing spondylitis (AS) in adults. The recently approved drug delivers quick disease control. Further, the approval demonstrates the company's continued advancement towards achieving its mission to accelerate the standards of care in rheumatic diseases.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel
  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers
By Route of Administration
  • Parenteral
  • Oral
By Drug Type
  • Analgesics
  • DMARDs
  • Corticosteroids
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • AbbVie, Inc.
  • Amgen, Inc.
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Musculoskeletal Disorders Drugs Market, by Distribution Channel
1.4.2 Global Musculoskeletal Disorders Drugs Market, by Route of Administration
1.4.3 Global Musculoskeletal Disorders Drugs Market, by Drug Type
1.4.4 Global Musculoskeletal Disorders Drugs Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Geographical Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Global Musculoskeletal Disorders Drugs Market by Distribution Channel
4.1 Global Drug Stores & Retail Pharmacies Market by Region
4.2 Global Hospital Pharmacies Market by Region
4.3 Global Online Providers Market by Region
Chapter 5. Global Musculoskeletal Disorders Drugs Market by Route of Administration
5.1 Global Parenteral Market by Region
5.2 Global Oral Market by Region
Chapter 6. Global Musculoskeletal Disorders Drugs Market by Drug Type
6.1 Global Analgesics Market by Region
6.2 Global DMARDs Market by Region
6.3 Global Corticosteroids Market by Region
6.4 Global Others Market by Region
Chapter 7. Global Musculoskeletal Disorders Drugs Market by Region
7.1 North America Musculoskeletal Disorders Drugs Market
7.1.1 North America Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.1.1 North America Drug Stores & Retail Pharmacies Market by Country
7.1.1.2 North America Hospital Pharmacies Market by Country
7.1.1.3 North America Online Providers Market by Country
7.1.2 North America Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.2.1 North America Parenteral Market by Country
7.1.2.2 North America Oral Market by Country
7.1.3 North America Musculoskeletal Disorders Drugs Market by Drug Type
7.1.3.1 North America Analgesics Market by Country
7.1.3.2 North America DMARDs Market by Country
7.1.3.3 North America Corticosteroids Market by Country
7.1.3.4 North America Others Market by Country
7.1.4 North America Musculoskeletal Disorders Drugs Market by Country
7.1.4.1 US Musculoskeletal Disorders Drugs Market
7.1.4.1.1 US Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.4.1.2 US Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.4.1.3 US Musculoskeletal Disorders Drugs Market by Drug Type
7.1.4.2 Canada Musculoskeletal Disorders Drugs Market
7.1.4.2.1 Canada Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.4.2.2 Canada Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.4.2.3 Canada Musculoskeletal Disorders Drugs Market by Drug Type
7.1.4.3 Mexico Musculoskeletal Disorders Drugs Market
7.1.4.3.1 Mexico Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.4.3.2 Mexico Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.4.3.3 Mexico Musculoskeletal Disorders Drugs Market by Drug Type
7.1.4.4 Rest of North America Musculoskeletal Disorders Drugs Market
7.1.4.4.1 Rest of North America Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.4.4.2 Rest of North America Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.4.4.3 Rest of North America Musculoskeletal Disorders Drugs Market by Drug Type
7.2 Europe Musculoskeletal Disorders Drugs Market
7.2.1 Europe Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.1.1 Europe Drug Stores & Retail Pharmacies Market by Country
7.2.1.2 Europe Hospital Pharmacies Market by Country
7.2.1.3 Europe Online Providers Market by Country
7.2.2 Europe Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.2.1 Europe Parenteral Market by Country
7.2.2.2 Europe Oral Market by Country
7.2.3 Europe Musculoskeletal Disorders Drugs Market by Drug Type
7.2.3.1 Europe Analgesics Market by Country
7.2.3.2 Europe DMARDs Market by Country
7.2.3.3 Europe Corticosteroids Market by Country
7.2.3.4 Europe Others Market by Country
7.2.4 Europe Musculoskeletal Disorders Drugs Market by Country
7.2.4.1 Germany Musculoskeletal Disorders Drugs Market
7.2.4.1.1 Germany Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.1.2 Germany Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.1.3 Germany Musculoskeletal Disorders Drugs Market by Drug Type
7.2.4.2 UK Musculoskeletal Disorders Drugs Market
7.2.4.2.1 UK Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.2.2 UK Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.2.3 UK Musculoskeletal Disorders Drugs Market by Drug Type
7.2.4.3 France Musculoskeletal Disorders Drugs Market
7.2.4.3.1 France Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.3.2 France Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.3.3 France Musculoskeletal Disorders Drugs Market by Drug Type
7.2.4.4 Russia Musculoskeletal Disorders Drugs Market
7.2.4.4.1 Russia Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.4.2 Russia Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.4.3 Russia Musculoskeletal Disorders Drugs Market by Drug Type
7.2.4.5 Spain Musculoskeletal Disorders Drugs Market
7.2.4.5.1 Spain Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.5.2 Spain Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.5.3 Spain Musculoskeletal Disorders Drugs Market by Drug Type
7.2.4.6 Italy Musculoskeletal Disorders Drugs Market
7.2.4.6.1 Italy Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.6.2 Italy Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.6.3 Italy Musculoskeletal Disorders Drugs Market by Drug Type
7.2.4.7 Rest of Europe Musculoskeletal Disorders Drugs Market
7.2.4.7.1 Rest of Europe Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.4.7.2 Rest of Europe Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.4.7.3 Rest of Europe Musculoskeletal Disorders Drugs Market by Drug Type
7.3 Asia Pacific Musculoskeletal Disorders Drugs Market
7.3.1 Asia Pacific Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.1.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
7.3.1.2 Asia Pacific Hospital Pharmacies Market by Country
7.3.1.3 Asia Pacific Online Providers Market by Country
7.3.2 Asia Pacific Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.2.1 Asia Pacific Parenteral Market by Country
7.3.2.2 Asia Pacific Oral Market by Country
7.3.3 Asia Pacific Musculoskeletal Disorders Drugs Market by Drug Type
7.3.3.1 Asia Pacific Analgesics Market by Country
7.3.3.2 Asia Pacific DMARDs Market by Country
7.3.3.3 Asia Pacific Corticosteroids Market by Country
7.3.3.4 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Musculoskeletal Disorders Drugs Market by Country
7.3.4.1 China Musculoskeletal Disorders Drugs Market
7.3.4.1.1 China Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.1.2 China Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.1.3 China Musculoskeletal Disorders Drugs Market by Drug Type
7.3.4.2 Japan Musculoskeletal Disorders Drugs Market
7.3.4.2.1 Japan Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.2.2 Japan Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.2.3 Japan Musculoskeletal Disorders Drugs Market by Drug Type
7.3.4.3 India Musculoskeletal Disorders Drugs Market
7.3.4.3.1 India Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.3.2 India Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.3.3 India Musculoskeletal Disorders Drugs Market by Drug Type
7.3.4.4 South Korea Musculoskeletal Disorders Drugs Market
7.3.4.4.1 South Korea Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.4.2 South Korea Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.4.3 South Korea Musculoskeletal Disorders Drugs Market by Drug Type
7.3.4.5 Singapore Musculoskeletal Disorders Drugs Market
7.3.4.5.1 Singapore Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.5.2 Singapore Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.5.3 Singapore Musculoskeletal Disorders Drugs Market by Drug Type
7.3.4.6 Malaysia Musculoskeletal Disorders Drugs Market
7.3.4.6.1 Malaysia Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.6.2 Malaysia Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.6.3 Malaysia Musculoskeletal Disorders Drugs Market by Drug Type
7.3.4.7 Rest of Asia Pacific Musculoskeletal Disorders Drugs Market
7.3.4.7.1 Rest of Asia Pacific Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.4.7.2 Rest of Asia Pacific Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.4.7.3 Rest of Asia Pacific Musculoskeletal Disorders Drugs Market by Drug Type
7.4 LAMEA Musculoskeletal Disorders Drugs Market
7.4.1 LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.1.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
7.4.1.2 LAMEA Hospital Pharmacies Market by Country
7.4.1.3 LAMEA Online Providers Market by Country
7.4.2 LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.2.1 LAMEA Parenteral Market by Country
7.4.2.2 LAMEA Oral Market by Country
7.4.3 LAMEA Musculoskeletal Disorders Drugs Market by Drug Type
7.4.3.1 LAMEA Analgesics Market by Country
7.4.3.2 LAMEA DMARDs Market by Country
7.4.3.3 LAMEA Corticosteroids Market by Country
7.4.3.4 LAMEA Others Market by Country
7.4.4 LAMEA Musculoskeletal Disorders Drugs Market by Country
7.4.4.1 Brazil Musculoskeletal Disorders Drugs Market
7.4.4.1.1 Brazil Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.1.2 Brazil Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.1.3 Brazil Musculoskeletal Disorders Drugs Market by Drug Type
7.4.4.2 Argentina Musculoskeletal Disorders Drugs Market
7.4.4.2.1 Argentina Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.2.2 Argentina Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.2.3 Argentina Musculoskeletal Disorders Drugs Market by Drug Type
7.4.4.3 UAE Musculoskeletal Disorders Drugs Market
7.4.4.3.1 UAE Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.3.2 UAE Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.3.3 UAE Musculoskeletal Disorders Drugs Market by Drug Type
7.4.4.4 Saudi Arabia Musculoskeletal Disorders Drugs Market
7.4.4.4.1 Saudi Arabia Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.4.2 Saudi Arabia Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.4.3 Saudi Arabia Musculoskeletal Disorders Drugs Market by Drug Type
7.4.4.5 South Africa Musculoskeletal Disorders Drugs Market
7.4.4.5.1 South Africa Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.5.2 South Africa Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.5.3 South Africa Musculoskeletal Disorders Drugs Market by Drug Type
7.4.4.6 Nigeria Musculoskeletal Disorders Drugs Market
7.4.4.6.1 Nigeria Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.6.2 Nigeria Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.6.3 Nigeria Musculoskeletal Disorders Drugs Market by Drug Type
7.4.4.7 Rest of LAMEA Musculoskeletal Disorders Drugs Market
7.4.4.7.1 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.4.7.2 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.4.7.3 Rest of LAMEA Musculoskeletal Disorders Drugs Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.6 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals and Trials:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Geographical Expansions:
8.4 UCB S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.6 Eli Lilly And Company
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.7 F. Hoffmann-La Roche Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 Merck & Co., Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.9 Novartis AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings